Reduces pocket depth. Sold as Minocin, Minocycline Hydrochloride, Arestin, Solodyn, Ximino and 4 more. Every FDA application for this active ingredient: 12 branded and 29 generic.
As of Nov 22, 2026, FDA lists 41 applications for Minocycline hydrochloride (sold as Minocin, Minocycline Hydrochloride, Arestin and others), first approved Jun 30, 1971, with 4 new uses approved and 0 published complete response letters.
| Jun 30, 1971 | MinocinNDA 50315 | Triax Pharmaceuticals | 57 | Discontinued |
| Oct 26, 1972 | MinocinNDA 50445 | Bausch Health | 26 | Discontinued |
| Oct 26, 1972 | MinocinNDA 50444 | Rempex Pharmaceuticals | 21 | Marketed |
| Aug 10, 1982 | Minocycline HydrochlorideNDA 50451 · New formulation or manufacturer | Triax Pharmaceuticals | 15 | Discontinued |
| May 31, 1990 | MinocinNDA 50649 · New dosage form | Bausch Health | 29 | Marketed |
| Jul 31, 1990 | DynacinANDA 63067 | Alvogen | 22 | Discontinued |
| Dec 30, 1991 | Minocycline HydrochlorideANDA 63065 | Watson Laboratories | 24 | Marketed |
| Dec 30, 1991 | Minocycline HydrochlorideANDA 63181 | Watson Labs Teva | 21 | Marketed |
| Mar 2, 1992 | Minocycline HydrochlorideANDA 63009 | Zydus | 33 | Marketed |
| Mar 2, 1992 | Minocycline HydrochlorideANDA 63011 | Zydus | 30 | Marketed |
| Mar 23, 1999 | Minocycline HydrochlorideANDA 65005 | Impax Laboratories | 7 | Marketed |
| Nov 30, 2000 | Minocycline HydrochlorideANDA 65062 | Torrent Pharmaceuticals | 10 | Marketed |
| Feb 16, 2001 | ArestinNDA 50781 · New dosage form | Orapharma | 11 | Marketed |
| Apr 16, 2003 | Minocycline HydrochlorideANDA 65131 | Strides Pharma International | 5 | Marketed |
| Jan 6, 2004 | Minocycline HydrochlorideANDA 65156 | Torrent Pharmaceuticals | 5 | Marketed |
| May 8, 2006 | SolodynNDA 50808 · New dosage form | Bausch Health | 13 | Discontinued |
| Dec 26, 2007 | Minocycline HydrochlorideANDA 65436 | Chartwell RX | 1 | Marketed |
| Mar 11, 2008 | Minocycline HydrochlorideANDA 65470 | Aurobindo Pharma | 9 | Marketed |
| Feb 3, 2009 | Minocycline HydrochlorideANDA 90024 | Impax Laboratories | 4 | Discontinued |
| Mar 17, 2009 | Minocycline HydrochlorideANDA 65485 | Barr Laboratories | 7 | Discontinued |
| Aug 13, 2009 | Minocycline HydrochlorideANDA 90422 | Sandoz | 4 | Marketed |
| Jul 20, 2010 | Minocycline HydrochlorideANDA 90911 | PharmoBedient | 2 | Discontinued |
| Nov 30, 2011 | Minocycline HydrochlorideANDA 91424 | Lupin | 3 | Marketed |
| Jul 11, 2012 | XiminoNDA 201922 · New dosage form | Journey Medical | 2 | Discontinued |
| May 13, 2013 | Minocycline HydrochlorideANDA 90867 | Sun Pharmaceutical Industries | 1 | Discontinued |
| Jan 29, 2016 | Minocycline HydrochlorideANDA 90217 | Sun Pharmaceutical Industries | 0 | Discontinued |
| May 8, 2017 | MinoliraNDA 209269 · New formulation or manufacturer | EPI HLTH | 0 | Discontinued |
| Jul 30, 2019 | Minocycline HydrochlorideANDA 201467 | Rising Pharmaceuticals | 1 | Discontinued |
| Aug 21, 2019 | Minocycline HydrochlorideANDA 202261 | Aurobindo Pharma | 2 | Marketed |
| Aug 21, 2019 | Minocycline HydrochlorideANDA 203443 | Rising Pharmaceuticals | 1 | Discontinued |
| Oct 18, 2019 | AmzeeqNDA 212379 · New dosage form | Journey Medical | 2 | Marketed |
| Dec 3, 2019 | Minocycline HydrochlorideANDA 91118 | Sun Pharmaceutical Industries | 1 | Discontinued |
| Dec 19, 2019 | Minocycline HydrochlorideANDA 204453 | Alkem Laboratories | 1 | Marketed |
| May 1, 2020 | Minocycline HydrochlorideANDA 213662 | Aurobindo Pharma | 1 | Marketed |
| May 28, 2020 | ZilxiNDA 213690 · New formulation or manufacturer | Journey Medical | 1 | Marketed |
| May 27, 2022 | Minocycline HydrochlorideANDA 215466 | Regcon Holdings | 1 | Marketed |
| Oct 7, 2022 | Minocycline HydrochlorideANDA 204394 | Sun Pharmaceutical Industries | 2 | Discontinued |
| Jun 16, 2023 | Minocycline HydrochlorideANDA 203553 | Zydus Pharmaceuticals (USA) | 1 | Discontinued |
| Nov 1, 2024 | EmrosiNDA 219015 · New formulation or manufacturer | Journey Medical | 0 | Marketed |
| — | MinocinANDA 62139 | Lederle Laboratories | 0 | Discontinued |
| — | Minocycline HydrochlorideANDA 214934 | Nexus Pharmaceuticals | 0 | Marketed |
| Minocycline HCl | Part D | $9.4M | +3% | 156,255 |
| Minocin | Part D | $733K | −5% | 54 |
| Emrosi | Part D | $339K | New | 132 |
| Zilxi | Part D | $145K | −66% | 162 |
| Amzeeq | Part D | $114K | −69% | 155 |
| Minocycline HCl ER | Part D | $109K | −10% | 138 |
Of the 37 whose ending is known, 32% met their primary endpoint, 16% missed it and 51% stopped early.
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA